Neuland Laboratories (NSE:NEULANDLAB) 3-Year RORE % : 7.28% (As of Mar. 2026)


NSE:NEULANDLAB Neuland Laboratories Ltd NSE:NEULANDLAB
92 GF Score
Price ₹18,944.00
GF Value ₹16,527.92
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Neuland Laboratories 3-Year RORE %?

Neuland Laboratories NSE:NEULANDLAB -0.23% 92 3-Year RORE % is 7.28 as of Mar. 2026. GuruFocus rates NSE:NEULANDLAB with a GF Score™ of 92/100 and a GF Value™ of ₹16,527.92 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 934 Drug Manufacturers companies, Neuland Laboratories ranks better than 56% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Neuland Laboratories's 3-Year RORE % for the quarter that ended in Mar. 2026 was 7.28%.

The industry rank for Neuland Laboratories's 3-Year RORE % or its related term are showing as below:

NSE:NEULANDLAB's 3-Year RORE % is ranked better than
56% of 934 companies
in the Drug Manufacturers industry
Industry Median: 3.09 vs NSE:NEULANDLAB: 7.28

Neuland Laboratories  (NSE:NEULANDLAB) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Neuland Laboratories 3-Year RORE % Related Terms


Neuland Laboratories 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Neuland Laboratories's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuland Laboratories 3-Year RORE % Chart

Neuland Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.71 28.08 46.85 14.07 7.28

Neuland Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.07 -5.69 -3.53 -18.40 7.28

NSE:NEULANDLAB vs ZTS, UTHR: 3-Year RORE % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuland Laboratories 3-Year RORE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Neuland Laboratories's 3-Year RORE % falls into.


NSE:NEULANDLAB
92GF Score
Neuland Laboratories Ltd NSE:NEULANDLAB
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuland Laboratories 3-Year RORE % Calculation

Neuland Laboratories's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 283.7-233.89 )/( 720.32-36 )
=49.81/684.32
=7.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 7.28 mean?
Neuland Laboratories (NSE:NEULANDLAB) has a 3-Year RORE % of 7.28 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Neuland Laboratories and its competitors. According to the industry distribution chart, Neuland Laboratories ranks #411 out of 934 companies in the Drug Manufacturers industry, placing it in the top 44%.
Is Neuland Laboratories' 3-Year RORE % too high?
Neuland Laboratories' current 3-Year RORE % is 7.28. The Drug Manufacturers industry median 3-Year RORE % is 3.09. Neuland Laboratories' value of 7.28 is 135.6% above this industry median. Based on the distribution chart, Neuland Laboratories ranks #411 out of 934 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Neuland Laboratories has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' 3-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Neuland Laboratories ranks #411 out of 934 companies for 3-Year RORE %. This puts Neuland Laboratories in the upper half of its industry. The industry median 3-Year RORE % is 3.09. Neuland Laboratories' value of 7.28 is 135.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.09, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuland Laboratories's current 3-Year RORE % of 7.28 is 135.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Neuland Laboratories and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuland Laboratories's current 3-Year RORE % is 7.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹16,527.92, compared to a current price of ₹18,944.00 — trading 14.6% above its estimated fair value. The current 3-Year RORE % is 7.28 and 135.6% above the Drug Manufacturers industry median of 3.09. Neuland Laboratories' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current 3-Year RORE % is 7.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued. The current stock price of ₹18,944.00 is trading 14.6% above its estimated GF Value™ of ₹16,527.92. GuruFocus considers Neuland Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:NEULANDLAB:

  • 3-Year RORE %: 7.28
  • GF Value™: ₹16,527.92 vs. price of ₹18,944.00 (14.6% above fair value)
  • GF Score™: 92/100 with 3 warning signs
  • Industry Position: 135.6% above the Drug Manufacturers median (#411 of 934)

No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Neuland Laboratories Business Description

Other Exchanges 524558:India
Address Road No. 82, Jubilee Hills, Plot No. 573A-III, Phoenix IVY Building, 11th Floor (5th Office Level), Hyderabad, TG, IND, 500033
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
92GF Score

Get the complete analysis for NSE:NEULANDLAB

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹18,944.00
Price
₹16,527.92
GF Value